Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
dimethindene (dimethindene maleate), phenylephrine
GlaxoSmithKline Consumer Healthcare S.A.
R01BA53
dimethindene (dimethindene maleate), phenylephrine
0,25mg/ml+ 2,5mg/ml
drops nasal
15ml glass vial
OTC
Registered
2019-11-27
GSK Consumer Healthcare S.A. CH-1260 Nyon, Switzerland Regulatory Affairs Vibrocil Nasal Drops Dimetindene maleate 0.025% + Phenylephrine base 0.25% SUMMARY OF PRODUCT CHARACTERISTICS Release date: 06 August 2019 Number of pages: 8 Property of GSK Consumer Healthcare S.A. Confidential May not be used, divulged, published or otherwise disclosed without the consent of GSK Consumer Healthcare S.A. GSK Consumer Healthcare S.A. CONFIDENTIAL Page 2 Summary of Product Characteristics Vibrocil 1. NAME OF THE MEDICINAL PRODUCT .................................................................. 3 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ........................................ 3 3. PHARMACEUTICAL FORM ....................................................................................... 3 4. CLINICAL PARTICULARS ......................................................................................... 3 4.1. Therapeutic indications ....................................................................................... 3 4.2. Posology and method of administration ............................................................. 3 4.3. Contra-indications............................................................................................... 3 4.4. Special warnings and precautions for use ........................................................... 4 4.5. Interactions with other medicinal products and other forms of interaction ........ 4 4.6. Pregnancy and lactation ...................................................................................... 4 4.7. Effects on ability to drive and use machines ...................................................... 4 4.8. Undesirable effects ............................................................................................. 4 4.9. Overdose ............................................................................................................. 5 5. PHARMACOLOGICAL PROPERTIES ....................................................................... 5 5.1. Pharmacodynam Read the complete document